Form 8-K Evoke Pharma Inc For: Jul 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Noble Financial Downgrades Evoke Pharma (EVOK) to Hold
July 19, 2016 6:41 AM EDTNoble Financial downgraded Evoke Pharma (NASDAQ: EVOK) from Buy to Hold.
For an analyst ratings summary and ratings history on Evoke Pharma click here. For more ratings news on Evoke Pharma click here.
Shares of Evoke Pharma closed at $2.89 yesterday.
... MoreFBR Affirms Evoke Pharma (EVOK) at 'Outperform' Following EVK-001 Phase 3 Endpoint Miss
July 18, 2016 11:21 AM EDTFBR & Co. affirmed Evoke Pharma, Inc. (NASDAQ: EVOK) with an Outperform rating and $17 price target after the company announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic diabetic gastroparesis. In this study, EVK-001, the Company's patented nasal delivery formulation of... More
